217 related articles for article (PubMed ID: 36683488)
21. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
22. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
24. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
[TBL] [Abstract][Full Text] [Related]
25. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
26. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
27. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.
Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):926-940. PubMed ID: 38482980
[TBL] [Abstract][Full Text] [Related]
28. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
30. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
32. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
[TBL] [Abstract][Full Text] [Related]
33. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
34. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
35. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
36. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
37. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
38. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Yoon DY; Lee S; Jang IJ; Kim M; Lee H; Kim S; Kim B; Song GS; Rhee SJ
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575565
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
